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So far, more than 1500 mutations have been reported in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Mutational
spectrum varies in accordance with geographic and/or ethnic origin. In this study, we have analyzed seven common CF mutations (p.F508del,
p.G542X, p.R1162X, p.N1303K, p.R334W, p.R553X and c.3120+1G>A) taking into account the ethnic origin of the Cuban population which
is mainly influenced by Spanish and sub-Sahara African contribution. All but p.N1303K have been detected in our patients, the p.F508del
being the most prevalent (37.9%). Overall, six mutations showed frequencies above 1% accounting for 55.5% of the Cuban CF alleles.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; CFTR gene; Cuban populationTable 1
Frequencies of cystic fibrosis mutations in the Cuban population (n=153)
Mutation CF alleles
Number %
p.F508del a 116 37.9
p.G542Xa 21 6.8
p.R334Wb 16 5.2
p.R553Xc 7 2.2
p.R1162Xa 6 2.0
c.3120+1G>Ad 4 1.3
p.N1303Ka 0 0
Total 170 55.5
a1. Introduction
In a previous study, the CF incidence in the Cuban population
has been estimated 1/5000 [1]. Taking into account the Spanish
and sub-Sahara African contribution to our population which
represent 60% and 40%, respectively [2], we have considered
starting the study in our patients analyzing the most common CF
mutations in those populations [3,4]. The aim of this work is the
molecular characterization of the Cuban CF population that will
allow us to confirm the clinical diagnosis and provide more
reliable genetic counselling to the patients and their families.
2. Materials and methods
2.1. Patients
The CF unrelated patients (n=153) were diagnosed by
clinical characteristics of the disease and positive sweat test⁎ Corresponding author. Tel.: +537 2715250.
E-mail address: tcollazo@infomed.sld.cu (T. Collazo).
1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.09.004(>60 mmol/L) [5]. In addition, the diagnoses were approved by
the CF National Commission. The study was approved by the
local Ethics Committee and informed written consent was
obtained from all participants or their parents.Newton et al. [6].
b Gasparini et al. [7].
c Cutting et al. [8].
d Zielenski et al. [9].
d by Elsevier B.V. All rights reserved.
Table 2
Comparative analysis of CF mutations identified in this study and other populations
Mutation (%) Cuba Spain a Chile b Argentina c Mexico d Brazil e Colombia f
p.F508del 37.9 51.7 45.0 60.26 40.7 48.4 41.8
p.G542X 6.8 7.7 7.0 4.49 6.2 8.8 3.8
p.R334W 5.2 1.8 2.0 1.93 – 2.5 0.5
p.R553X 2.2 0.4 1.0 1.28 0.5 0.6 –
p.R1162X 2.0 1.3 2.0 0.64 – 2.5 1.1
c.3120+1G>A 1.3 – – 0.64 – 4.7 g 0.5
p.N1303K 0 2.9 – 5.13 2.0 2.5 0.5
a Alonso et al. [3].
b Repetto et al. [12].
c Oller et al. [13].
d Orozco et al. [14].
e Bernardino et al. [15].
f Keyeux et al. [16].
g Cabello GM et al. [17].
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DNA purification was performed by standard procedures
from leucocytes. Seven CFmutations were analyzed: p.F508del,
p.G542X, p.R1162X, p.N1303K, p.R334W, p.R553X, c.3120+
1G>A in all patients.
Amplification Refractory of Mutations Specific (ARMS) [6]
was carried out to detect four mutations: p.F508del, p.G542X,
p.R1162X, p.N1303K. The remaining three mutations, p.R334W
[7], p.R553X [8] and c.3120+1G>A [9], were directly inves-
tigated by enzymatic digestion of the corresponding PCR products.
3. Results and discussion
CF mutational spectrum has been observed specific for
different populations [10]. The present Cuban population is the
result of a mixing contribution from Spanish and sub-Sahara
African populations. Taking into account this ethnic origin we
have performed direct analysis of seven common CF mutations.
We have identified six out of seven mutations accounting for
55.5% of the CF alleles. All six mutations showed frequencies
above 1% indicating enough efficiency from our preliminary
strategy considering the ethnic composition in Cuba (Table 1).
In contrast with our previous data [11] a lower frequency for
p.F508del mutation (37.9%) was found, this discrepancy could
be likely due to clinical criteria inclusion followed here.
However, the present estimated prevalence is similar to other
Latin American countries (Table 2) [3,12–17]. Concerning the
frequency of p.G542X mutation (6.8%), a high prevalence of
this mutation has also been reported in Mexico (6.2%) [14] and
Costa Rica (25%) [18], strongly suggesting the Spanish
influence in all cases. Such founder effect could also be
postulated for p.R334W mutation (5.2% in Cuba).
As expected regarding our African ancestry the c.3120+
1G>A mutation was found in 1.3% of the CF alleles. The
higher frequency of this mutation in Latin America has been
reported in Brazil (Table 2) [17].
On the other hand, our data point out a high molecular
heterogeneity in Cuban CF population in agreement with
previous reports from us and other Latin American countries[12–17]. This CF variable spectrum in Latin American
countries has been recently reviewed by Pérez et al. [19]. The
present work represents the major contribution to the molecular
profile of CF in Cuban population with six mutations
accounting for 55.5% of alleles, which will allow us to design
one specific diagnostic panel for CF mutations. Furthermore,
our results will contribute to improve the genetic counselling for
the patients and their relatives. Nowadays, we are performing an
extensive CFTR gene analysis to accurately define the specific
molecular profile of CF in Cuba.
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